China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc. to evaluate the combined potential of Antengene’s bispecific antibody (BsAb) and Celularity’s cryopreserved natural killer (NK) cell therapy derived from human placental hematopoietic stem cells. Financial terms were not disclosed.
Collaboration Details
The partnership aims to assess two hypotheses:
- BsAb can activate NK cells in the tumor microenvironment (TME) while cross-linking immune checkpoint inhibitors (ICIs), enhancing antitumor responses with tumor-associated antigen (TAA) antibody drugs.
- The antibody drug boosts NK cell proliferation and persistence in the TME. The combo will be tested with antibodies targeting TAAs.
Celularity’s Technology
Celularity develops allogeneic cell therapies from postpartum placental cells, including cryopreserved NK cells, CAR T cells, and mesenchymal-like stromal cells (ASC) for cancer and degenerative diseases.-Fineline Info & Tech
